Dosage regimen for an s1p receptor modulator or agonist

作者: Erik Wallstroem

DOI:

关键词:

摘要: This invention relates to a method of treating multiple sclerosis in mammalian patient, preferably human, need such treatment, comprising administering said human an S1P receptor modulator or agonist according dosing regimen that is determined with reference the patient's blood lymphocyte count.

参考文章(11)
Christian Schnell, Peter C. Hiestand, S1P receptor modulators for treating multiple sclerosis ,(2007)
Robert Schmouder, Olivier David, Craig Boulton, Irene Hunt, Ana de Vera, Pascale Burtin, Thomas Dumortier, Dosage regimen of an s1p receptor modulator ,(2010)
Ludwig Kappos, Jack Antel, Giancarlo Comi, Xavier Montalban, Paul O'Connor, Chris H. Polman, Tomas Haas, Alexander A. Korn, Goeril Karlsson, Ernst W. Radue, Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis The New England Journal of Medicine. ,vol. 355, pp. 1124- 1140 ,(2006) , 10.1056/NEJMOA052643
Robert Schmouder, Denise Serra, Yibin Wang, John M. Kovarik, John DiMarco, Thomas L. Hunt, Marie-Claude Bastien, FTY720: Placebo-Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects The Journal of Clinical Pharmacology. ,vol. 46, pp. 895- 904 ,(2006) , 10.1177/0091270006289853
Yuan Mi, Nathanael Schiander Gray, Tao Jiang, Wenqi Gao, Shifeng Pan, Yi Fan, Immunosuppressant compounds and compositions ,(2004)
Silke Appel-Dingemanse, John M. Kovarik, Dosage Regimen of an S1P Receptor Agonist ,(2005)
Thomas Baumruker, Diana Mechtcheriakova, Peter T. Lassota, Kenneth Richard La Montagne, Jeanette Marjorie Wood, Volker Brinkmann, Use of EDG receptor binding agents in cancer ,(2003)
M. Mehling, V. Brinkmann, J. Antel, A. Bar-Or, N. Goebels, C. Vedrine, C. Kristofic, J. Kuhle, R.L.P. Lindberg, L. Kappos, FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis Neurology. ,vol. 71, pp. 1261- 1267 ,(2008) , 10.1212/01.WNL.0000327609.57688.EA